3.6500 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||3.4200 x 1300|
|Ask||3.6500 x 3000|
|Day's Range||3.4300 - 3.8700|
|52 Week Range||2.2400 - 11.2800|
|Beta (3Y Monthly)||3.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.33|
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Investors need to pay close attention to Genocea Biosciences (GNCA) stock based on the movements in the options market lately.
All the shares in the offering will be sold by Genocea. In addition, Genocea expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock sold in the public offering. SVB Leerink and Stifel are acting as joint book-running managers for the offering.
Genocea Biosciences (NASDAQ: GNCA ) shares rallied higher after the company presented results from lead neoantigen vaccine at the annual meeting of the American Society of Clinical Oncology 2019. Genocea ...
Shares of Genocea Biosciences Inc. surged 101% in premarket trade Monday after the biotech announced promising data from an early-stage clinical trial of its lead drug candidate, a personalized cancer vaccine. Genocea's vaccine, called GEN-009, uses neoantigens -- antigens corresponding to tumor mutations that a patient's immune system sees as foreign to the body -- to prime the immune system to find and kill tumors. The company is currently running a Phase 1/2 clinical trial to evaluate the vaccine's safety and efficacy. So far, immune-response data is available for five patients, and the therapy induced T-cell responses to 91% of the vaccine neoantigens given to the patients, according to the company. Also, 47% of the neoantigens were able to elicit ex vivo CD8+ T-cell responses, the company said. Shares of Genocea have gained 144% in the year to date through Friday. The S&P 500 has gained 9.8%.
The results were presented in a poster over the weekend at this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO 2019). In the five patients for whom immune response results are available to date, GEN-009 monotherapy elicited T cell responses to 91% of the vaccine neoantigens administered.
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
Poster presentation tomorrow, June 1st at 8:00 am CT in Poster Hall A Conference call and webcast to discuss results Monday, June 3rd at 8:30 am ET CAMBRIDGE, Mass., May 31,.
CAMBRIDGE, Mass., May 16, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced a.
“To date, we have analyzed full immune response data from three patients following their priming series of three vaccinations and have detected immune responses to 93% of the total administered neoantigens, a response rate that would be best-in-class if seen across the full vaccinated cohort,” said Tom Davis, M.D., Genocea’s Chief Medical Officer. “We are studying a diverse group of patients and, despite this variability, we are seeing consistently broad immune responses, including ex vivo CD8+ T cell responses, which have not previously been detected after monotherapy with a neoantigen vaccine.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 15 cents. Losses, adjusted for non-recurring costs, were 9 cents per share. The company's shares closed at 76 cents. ...
Company anticipates presenting first GEN-009 immunogenicity data at ASCO 2019 Conference call today at 9:00 am ET CAMBRIDGE, Mass., April 30, 2019 -- Genocea Biosciences,.
CAMBRIDGE, Mass., April 23, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its.
CAMBRIDGE, Mass., April 03, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that.
CAMBRIDGE, Mass., April 02, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer immunotherapies, today announced the.
CAMBRIDGE, Mass., March 06, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that.
Company advancing lead clinical-stage neoantigen cancer vaccine candidate and expanding pipeline into adoptive cell therapy Diantha Duvall to join as CFO, bringing broad life.
CAMBRIDGE, Mass., Feb. 21, 2019 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it.
Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered into a private placement with certain existing and new investors providing for the purchase of up to approximately $39.2 million of its common stock and warrants to purchase shares of Genocea common stock, in two closings. In the first closing, Genocea will offer 25.6 million shares of common stock and 4.25 million pre-funded warrants to purchase common stock, along with accompanying warrants to purchase 0.25 shares of common stock for each share of common stock or pre-funded warrant purchased by an investor, for expected aggregate gross proceeds to Genocea of approximately $15.0 million (before deducting fees to the placement agents and other offering expenses payable by Genocea).